Novo signs $1.4 billion Orbis oral deal as CagriSema data land

The wire

1. 01Novo Nordisk signed a development and licensing agreement with Orbis Medicines on September 17 worth up to $1.4 billion for oral cardiometabolic therapies, including upfront and milestone payments, royalties and an equity stake.
2. 02CagriSema showed 12.4% average weight loss in REIMAGINE-5 in diabetes patients and 21% weight reduction versus placebo at 1.0 mg in an obesity study, with an FDA decision on weight control expected in the fourth quarter.
3. 03Shares fell as much as 9% on Capital Markets Day and are down 22% year to date, signaling investor doubt about CEO Mike Doustdar's target of five-plus blockbusters by 2030.

From the source

Novo Nordisk's Oral Pivot Takes Shape as CagriSema Data Land and Orbis Deal Tops $1.4 Billion

Novo Nordisk used a packed stretch of announcements to press its case that the next chapter of the obesity and diabetes market will be written in tablets, not syringes. The Danish drugmaker capped the run with a development and licensing agreement signed on September 17 with Orbis Medicines, valued at as much as USD 1.4 billion, aimed at oral therapies for cardiometabolic disease. The pact bundles